Lymphoma drug trial stopped early after enrolling only 5 patients
NCT ID NCT03990961
First seen Feb 22, 2026 · Last updated May 15, 2026 · Updated 8 times
Summary
This study tested the drug pembrolizumab in people with a hard-to-treat type of lymphoma (DLBCL) that has certain gene changes (PD-L1 alterations). The goal was to see if the drug could shrink tumors. However, the study was stopped early and only 5 people took part, so the results are very limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Chicago Medicine
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.